'This was the first time we've ever shown ... retreatment is an effective strategy,' says expert
— "This was the first time we've ever shown ... retreatment is an effective strategy," says expert
by Gregory Laub, Senior Director, Video, MedPage Today
July 15, 2026
• 3 min read
At the International Symposium on Pediatric Neuro-Oncology (ISPNO), investigators reported prospective evidence supporting retreatment with the MEK inhibitor selumetinib (Koselugo) in children with recurrent low-grade glioma.
FDA grants traditional approval to Retevmo for RET fusion-positive solid tumors
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - GSK (NYSE:GSK)
But phase III study testing selinexor plus ruxolitinib splits on its main goals
The FDA has granted traditional approval to selpercatinib for adults and children aged 2 years and older with locally advanced or…
Substantial EFS improvement with selpercatinib in RET fusion-positive disease
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be…
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at…
Regimen could be new standard of care for treating children with de novo disease, researcher says
